Hereditary Causes of Nephrolithaisis and Kidney Failure

肾结石和肾衰竭的遗传原因

• 批准号: 8144867
• 负责人: Dawn Schmautz Milliner
• 金额: $ 122.91万
• 依托单位: MAYO CLINIC ROCHESTER
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-08 至 2014-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8144867
• 关键词: Hereditary; Causes; Nephrolithaisis; Kidney; Failure

DESCRIPTION (provided by applicant): 300 words Four inborn errors of metabolism lead to high concentrations of insoluble mineral salts in the urine and severe, recurrent nephrolithiasis. Patients with primary hyperoxaluria (PH), cystinuria, APRT deficiency (dihydroxyadeninuria, DMA), and Dent disease experience stones beginning in childhood. Deposition of crystals in kidney tissue and loss of kidney function is observed in all. Disease expression varies widely. Some PH patients, for example, progress to end stage renal failure during infancy, while others maintain kidney function until middle age. This variability is poorly understood. Modifiers of disease expression, if identified, offer promise as potential new treatment strategies. Yet progress toward effective treatment has been slow. Small numbers of widely scattered patients make rigorous characterization and longitudinal assessment of disease expression difficult. The ability to test efficacy of new treatments is limited since few patients are available for clinical trials. To address this problem, we will build on previous, successful work of the International Primary Hyperoxaluria Registry (IPHR) to expand the IPHR and establish secure, web-based registries and tissue banks for cystinuria, DHA, and Dent disease. Longitudinal studies of individual patients conducted in each disease will emphasize generation of testable hypotheses and identification of well characterized cohorts of patients for future clinical trials. All four diseases appear mediated by renal deposition of crystals, and the cellular response, which in turn, appears modulated by urinary protein inhibitors. Therefore, there is great potential for synergy to understand the impact of the urinary proteome and renal cell biology in disease progression. An outstanding consortium of clinical scientists with unique expertise and access to patient with these diagnoses will address this work. Multidisciplinary collaboration will occur through joint activities with the relevant patient support organizations, regular communications among Consortium members, and open sharing of newly developed resources with patients, members of the medical community and scientists. PUBLIC HEALTH RELEVANCE: The Consortium for Hereditary Causes of Nephrolithiasis and Renal Failure is highly suited to accomplish the characterization and longitudinal assessment needed to facilitate discovery of biomarkers of disease risk, disease activity, and response to therapy for four rare diseases that share similar mechanisms and severe disease manifestations. This work will address barriers of rare diseases research through vigorous multidisciplinary cooperation.

描述（由申请人提供）：300字四种先天性代谢缺陷导致尿液中高浓度的不溶性矿物盐和严重的复发性肾结石。患有原发性高尿酸（PH）、胱氨酸尿、APRT缺乏症（二羟腺苷尿症，DMA）和登特病的患者在儿童时期就开始出现结石。所有患者均观察到肾组织中晶体沉积和肾功能丧失。疾病表现差异很大。例如，一些PH患者在婴儿期发展为终末期肾衰竭，而另一些PH患者则将肾功能维持到中年。人们对这种可变性知之甚少。疾病表达的修饰物，如果确定，提供作为潜在的新的治疗策略的承诺。然而，有效治疗的进展一直很缓慢。少数广泛分散的患者使严格的表征和疾病表达的纵向评估变得困难。测试新疗法疗效的能力有限，因为可用于临床试验的患者很少。为了解决这个问题，我们将在国际原发性高尿酸血症登记处（IPHR）以前的成功工作的基础上，扩大IPHR，并建立安全的，基于网络的胱氨酸尿症，DHA和Dent病的登记处和组织库。在每种疾病中进行的个体患者的纵向研究将强调产生可检验的假设，并为未来的临床试验确定特征良好的患者队列。所有这四种疾病似乎都是由晶体的肾沉积介导的，而细胞反应反过来又受到尿蛋白抑制剂的调节。因此，了解尿蛋白质组和肾细胞生物学在疾病进展中的影响有很大的协同潜力。一个杰出的临床科学家联盟，具有独特的专业知识和访问患者与这些诊断将解决这项工作。多学科合作将通过与相关患者支持组织的联合活动，联盟成员之间的定期沟通以及与患者，医学界成员和科学家开放共享新开发的资源来实现。 公共卫生相关性：肾结石和肾衰竭遗传原因联盟非常适合完成所需的表征和纵向评估，以促进发现疾病风险，疾病活动和对四种罕见疾病治疗反应的生物标志物，这些疾病具有相似的机制和严重的疾病表现。这项工作将通过积极的多学科合作解决罕见病研究的障碍。